Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Next Previous
Trial Profile

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Anastrozole/testosterone (Primary) ; Elacestrant (Primary) ; Endoxifen (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary)
  • Indications Breast cancer; Ductal carcinoma
  • Focus Therapeutic Use
  • Acronyms RECAST DCIS; RECAST DCIS Platform Trial; RECAST Trial
  • Sponsors Quantum Leap Healthcare Collaborative

Most Recent Events

  • 15 Dec 2025 According to an Atossa Therapeutics media release, company presented clinical trial updates on (Z)-endoxifen at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025, in San Antonio, TX.
  • 21 Oct 2025 According to Atossa Therapeutics media release, enrollment started in Jan 2024 and 50 patients have been enrolled toward a target of 400 across 17 activated clinical sites, with additional sites planned.
  • 03 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top